RS60830B1 - Benzoksazinonski derivati za lečenje kožnih bolesti - Google Patents
Benzoksazinonski derivati za lečenje kožnih bolestiInfo
- Publication number
- RS60830B1 RS60830B1 RS20201128A RSP20201128A RS60830B1 RS 60830 B1 RS60830 B1 RS 60830B1 RS 20201128 A RS20201128 A RS 20201128A RS P20201128 A RSP20201128 A RS P20201128A RS 60830 B1 RS60830 B1 RS 60830B1
- Authority
- RS
- Serbia
- Prior art keywords
- treatment
- prophylaxis
- klk7
- prevention
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1430003 | 2014-01-23 | ||
| EP15740572.1A EP3097085B1 (en) | 2014-01-23 | 2015-01-22 | Benzoxazinone derivatives for treatment of skin diseases |
| PCT/SE2015/050062 WO2015112081A1 (en) | 2014-01-23 | 2015-01-22 | Benzoxazinone derivatives for treatment of skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60830B1 true RS60830B1 (sr) | 2020-10-30 |
Family
ID=53681747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20201128A RS60830B1 (sr) | 2014-01-23 | 2015-01-22 | Benzoksazinonski derivati za lečenje kožnih bolesti |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9695194B2 (enExample) |
| EP (1) | EP3097085B1 (enExample) |
| JP (1) | JP6448651B2 (enExample) |
| CN (1) | CN106132941B (enExample) |
| AU (1) | AU2015209761B2 (enExample) |
| CA (1) | CA2934025C (enExample) |
| CY (1) | CY1123477T1 (enExample) |
| DK (1) | DK3097085T3 (enExample) |
| ES (1) | ES2820868T3 (enExample) |
| HR (1) | HRP20201500T1 (enExample) |
| HU (1) | HUE051296T2 (enExample) |
| LT (1) | LT3097085T (enExample) |
| PL (1) | PL3097085T3 (enExample) |
| PT (1) | PT3097085T (enExample) |
| RS (1) | RS60830B1 (enExample) |
| SI (1) | SI3097085T1 (enExample) |
| SM (1) | SMT202000557T1 (enExample) |
| WO (1) | WO2015112081A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3097085T3 (da) * | 2014-01-23 | 2020-10-26 | Sixera Pharma Ab | Benzoxazinonderivater til behandling af hudsygdomme |
| KR102579996B1 (ko) | 2015-05-13 | 2023-09-18 | 니혼노야쿠가부시키가이샤 | 안트라닐산 에스테르 화합물 또는 이의 염류 및 해당 화합물을 함유하는 농원예용 살균제 및 이의 사용 방법 |
| EP3402572B1 (en) * | 2016-01-13 | 2022-03-16 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| KR20250070121A (ko) | 2017-06-16 | 2025-05-20 | 아지트라 인코포레이티드 | Lekti 발현 재조합 미생물을 사용하는 네테르톤 증후군의 치료를 위한 조성물 및 방법 |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| WO2019204580A1 (en) | 2018-04-20 | 2019-10-24 | Children's Hospital Medical Center | Blood biomarker for eosinophilic gastrointestinal disorders |
| GB201809378D0 (en) | 2018-06-07 | 2018-07-25 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US12297501B2 (en) | 2019-02-25 | 2025-05-13 | Children's Hospital Medical Center | Methods for diagnosing and treating eosinophilic gastritis |
| AR119997A1 (es) | 2019-09-18 | 2022-01-26 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso |
| TW202126631A (zh) | 2019-10-01 | 2021-07-16 | 美商分子皮膚療法公司 | 作為klk5/7雙重抑制劑之苯并酮化合物 |
| GB202001447D0 (en) * | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| BR102020009679A2 (pt) | 2020-05-14 | 2021-11-23 | Fundação Universidade Federal Do Abc - Ufabc | Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele |
| TW202304890A (zh) * | 2021-04-14 | 2023-02-01 | 美商百歐克斯製藥公司 | Klk5雙環雜芳香族抑制劑 |
| EP4346761A1 (en) | 2021-06-01 | 2024-04-10 | Sixera Pharma AB | Oil-in-water emulsion of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,l-benzoxazin-4-one |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB115399A (en) * | 1917-03-28 | 1918-04-29 | Reginald Guley Lewis | Improved Delivery mechanism for Coin-freed Apparatus and the like. |
| GB1153994A (en) | 1965-07-21 | 1969-06-04 | Aspro Nicholas Ltd | Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them |
| WO1999048878A1 (en) * | 1998-03-24 | 1999-09-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| DK1631295T3 (da) * | 2003-06-06 | 2010-06-21 | Arexis Ab | Anvendelse af kondenserede heterocykliske forbindelser som SCCE-inhibitorer ved behandling af hudsygdomme |
| TWI419884B (zh) * | 2010-06-24 | 2013-12-21 | Univ Chang Gung | 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物 |
| DK3097085T3 (da) * | 2014-01-23 | 2020-10-26 | Sixera Pharma Ab | Benzoxazinonderivater til behandling af hudsygdomme |
-
2015
- 2015-01-22 DK DK15740572.1T patent/DK3097085T3/da active
- 2015-01-22 SI SI201531393T patent/SI3097085T1/sl unknown
- 2015-01-22 JP JP2016544672A patent/JP6448651B2/ja active Active
- 2015-01-22 PL PL15740572T patent/PL3097085T3/pl unknown
- 2015-01-22 HU HUE15740572A patent/HUE051296T2/hu unknown
- 2015-01-22 SM SM20200557T patent/SMT202000557T1/it unknown
- 2015-01-22 HR HRP20201500TT patent/HRP20201500T1/hr unknown
- 2015-01-22 EP EP15740572.1A patent/EP3097085B1/en active Active
- 2015-01-22 RS RS20201128A patent/RS60830B1/sr unknown
- 2015-01-22 US US15/113,750 patent/US9695194B2/en active Active
- 2015-01-22 WO PCT/SE2015/050062 patent/WO2015112081A1/en not_active Ceased
- 2015-01-22 LT LTEP15740572.1T patent/LT3097085T/lt unknown
- 2015-01-22 ES ES15740572T patent/ES2820868T3/es active Active
- 2015-01-22 CN CN201580005383.4A patent/CN106132941B/zh active Active
- 2015-01-22 AU AU2015209761A patent/AU2015209761B2/en active Active
- 2015-01-22 CA CA2934025A patent/CA2934025C/en active Active
- 2015-01-22 PT PT157405721T patent/PT3097085T/pt unknown
-
2017
- 2017-06-05 US US15/614,462 patent/US10072024B2/en active Active
-
2020
- 2020-10-20 CY CY20201100988T patent/CY1123477T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3097085T (pt) | 2020-10-08 |
| US10072024B2 (en) | 2018-09-11 |
| US20170002021A1 (en) | 2017-01-05 |
| JP2017503798A (ja) | 2017-02-02 |
| US20170267692A1 (en) | 2017-09-21 |
| JP6448651B2 (ja) | 2019-01-09 |
| LT3097085T (lt) | 2020-10-12 |
| PL3097085T3 (pl) | 2021-01-11 |
| CA2934025A1 (en) | 2015-07-30 |
| CY1123477T1 (el) | 2022-03-24 |
| EP3097085A4 (en) | 2017-08-09 |
| CN106132941A (zh) | 2016-11-16 |
| SMT202000557T1 (it) | 2020-11-10 |
| HUE051296T2 (hu) | 2021-03-01 |
| CN106132941B (zh) | 2018-04-06 |
| HRP20201500T1 (hr) | 2020-12-25 |
| WO2015112081A1 (en) | 2015-07-30 |
| DK3097085T3 (da) | 2020-10-26 |
| EP3097085A1 (en) | 2016-11-30 |
| AU2015209761A1 (en) | 2016-07-07 |
| CA2934025C (en) | 2022-06-07 |
| SI3097085T1 (sl) | 2020-11-30 |
| US9695194B2 (en) | 2017-07-04 |
| EP3097085B1 (en) | 2020-07-29 |
| AU2015209761B2 (en) | 2018-11-29 |
| ES2820868T3 (es) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS60830B1 (sr) | Benzoksazinonski derivati za lečenje kožnih bolesti | |
| Dong et al. | Mmp-9, a potential target for cerebral ischemic treatment | |
| Oyamada et al. | Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion | |
| Kurzepa et al. | Role of MMP-2 and MMP-9 and their natural inhibitors in liver fibrosis, chronic pancreatitis and non-specific inflammatory bowel diseases | |
| Bezerra et al. | Plasminogen activators direct reorganization of the liver lobule after acute injury | |
| Ruddy et al. | Multidimensional contribution of matrix metalloproteinases to atherosclerotic plaque vulnerability: multiple mechanisms of inhibition to promote stability | |
| Chakraborti et al. | Implications of calpains in health and diseases | |
| JP6932386B2 (ja) | 新しいカリクレイン７阻害剤 | |
| Ni et al. | Tryptase inhibitors: a patent review | |
| JP2017505299A5 (enExample) | ||
| Docevska et al. | Cathepsin C: structure, function, and pharmacological targeting | |
| HK1229792B (en) | Benzoxazinone derivatives for treatment of skin diseases | |
| HK1229792A1 (en) | Benzoxazinone derivatives for treatment of skin diseases | |
| Liu et al. | Broadening horizons: exploring the cathepsin family as therapeutic targets for Alzheimer’s disease | |
| Zielińska‐Przyjemska et al. | Modulatory effect of chiral nonsteroidal anti‐inflammatory drugs on apoptosis of human neutrophils | |
| Triniac | Νeural respοnse in ischemic strοke: mοdulatiοn οf autοphagy and tΡA cleavage | |
| Andrieu-Abadie | Lysosomal Proteases in Cell Death | |
| HK1229791A1 (en) | New kallikrein 7 inhibitors | |
| HK1229791B (zh) | 新的激肽释放酶7抑制剂 | |
| Stevens | Protease-Activated Receptors, Tryptases, and Mast-Cell-Mediated Immune Responses in the Lung |